Satorious $SRT revising guidance downward for 2023. EBITDA margin also guided down.

They are seeing recovery in demand but it is slower than expected. Some positive in the negative news. $TMO $DHR $MTD

Our latest deep dive is out, this month we studies and wrote about Ascendis Pharma $ASND. This was our 10th deep dive.

You can read the post here:

We are in the middle of writing a deep dive on a mid-cap pharma company that could potentially be a multi-bagger for investors, coming out at the end of the week.

Past deep dives include $CRSP, $VRTX, $ISRG, $SRPT, $ALNY, $REGN, $NVO, $TMO, $HALO, $DHR

If you don't want to miss it, be sure to subscribe to our newsletter at www.biocompounding.com

Are you interested in the pharmaceutical industry?

One of the hottest trends currently are CAR-T cells. These are cell therapies, in which T cells (immune cells) are taken from the individual, modified by genetic engineering and injected into the individual to fight the cancer cells.

Interested to learn more about how CAR-T cell therapy works, its manufacturing process and the current bottleneck, you can read all about it in our blog post here.

If you enjoyed the read, be sure to subscribe to our newsletter, upvote our post and share it with the community so everyone can learn and grow.

Are you interested in the pharmaceutical industry?

One of the hottest trends currently are CAR-T cells. These are cell therapies, in which T cells (immune cells) are taken from the individual, modified by genetic engineering and injected into the individual to fight the cancer cells.

Interested to learn more about how CAR-T cell therapy works, its manufacturing process and the current bottleneck, you can read all about it in our blog post here.

If you enjoyed the read, be sure to subscribe to our newsletter, upvote our post and share it with the community so everyone can learn and grow.

In June we ran a valuation exercise for $DHR to determine the fair value for the company and the price at which it will be an attractive buy.

The modeling was done before the spin out of $VLTO, and shares our assumptions for the year. Read all the details in the link below.

Biocompounding is an independent equity research blog that focuses on the biotech/pharma and healthcare sector. You can subscribe to our blog to read all our free articles and premium articles for paying subscribers.

Our latest deep dive is on $HALO. Read it here: https://www.biocompounding.com/halozyme-therapeutics-halo-deep-dive/